Fox Chase Cancer Center and Oryzon Genomics S.A. formed a collaboration to test the safety and efficacy of the drug iadademstat in patients with pulmonary and extrapulmonary neuroendocrine carcinomas, which are rare and heterogeneous cancers arising from neuroendocrine cells, and small cell lung cancer.
J. Leonard Lichtenfeld joined SpotitEarly, an Israel-based technology company transforming cancer screening by harnessing the power of artificial intelligence and dogs to detect cancer early, as chief medical officer.
